DUODENAL CYTOCHROME B (CYBRD1) FERRIC REDUCTASE FUNCTIONAL STUDIES IN CELLS,Metallomics

当前位置： X-MOL 学术 › Metallomics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

DUODENAL CYTOCHROME B (CYBRD1) FERRIC REDUCTASE FUNCTIONAL STUDIES IN CELLS
Metallomics ( IF 2.9 ) Pub Date : 2017-09-15 00:00:00 , DOI: 10.1039/c7mt00254h
F. Schlottmann _{1,

2,

3} , M. Vera-Aviles _{1,

2,

3} , G. O. Latunde-Dada _{1,

2,

3}

Affiliation

Dietary non-heme ferric iron is reduced by the ferric reductase enzyme, duodenal cytochrome b (Dcytb), before absorption by the divalent metal transporter 1 (DMT1). A single nucleotide polymorphism (SNP rs10455 mutant) that is located in the last exon of Dcytb gene was reported in C282Y haemochrotomatosis HFE subjects. The present work therefore investigated the phenotype of this mutant Dcytb in Chinese hamster ovary (CHO) cells. These cultured cells were transfected with either wild type (WT) or the SNP vector plasmids of Dcytb. Ferric reductase assays were performed in Dcytb transgenic CHO cells using the ferrozine spectrophometric assay protocol. The Dcytb SNP rs10455 showed a gain of function capability since ferric reductase activity increased significantly (P<0.01) in the transgenic cells. Increased ferric reductase activity was found when CHO cells were pretreated with modulators of Dcytb protein expression. Although ferric reductase in endogenous CHO cells increased with deferoxamine or CoCl2, iron loading with ferric ammonium citrate (FAC) had the opposite effect. Taken together, the study reveals a gain-of-function phenotype for Dcytb rs10455 mutation that could be a putative modifier of colorectal cancer risk, with attendant variability in penetrance among human HFE C282Y homozygotes.

更新日期：2017-09-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11